Table of Contents Author Guidelines Submit a Manuscript

Regenerative Medicine

Call for Papers

Regenerative medicine would be the most exciting area in recent scientific topics. In the history of human gene therapy, the severe combined immunodeficiency caused by the absence of adenosine deaminase (SCID-ADA) was the first monogenic disorder for which gene therapy was developed in 1990. Over 30 patients have been treated worldwide using the current protocols, and recent trials provided the demonstration of long-term clinical efficacy of HSC gene therapy for SCID-ADA in combination with gene and cell therapy. We have now several options, such as gene therapy and/or cell therapy with advanced technology (i.e., cell sheet or drug delivery system), to fight against the severe diseases.

The main focus of this special issue will be on the new and exciting therapy for cardiovascular diseases, cancer, or inflammatory diseases, which includes the range from basic to clinical studies. We will take particular interest in review or original articles for clinical trials or translational research. The special issue will teach us the recent progression in each field which could give us the exciting knowledge and ideas. Potential topics include, but are not limited to:

  • Antiangiogenic therapy for cancer
  • Cell and tissue engineering for heart failure
  • Virosome therapy for cancer
  • Therapeutic angiogenesis for ischemic disease
  • Vaccine for cardiovascular disease
  • Oligodeoxynucleotide therapy
  • Biomaterials and tissue interaction
  • Molecular mechanisms of atherosclerosis
  • Stem cell therapy for heart failure

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Manuscript DueFriday, 11 October 2013
First Round of ReviewsFriday, 3 January 2014
Publication DateFriday, 28 February 2014

Lead Guest Editor

  • Ryuichi Morishita, Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan

Guest Editors

  • Yasufumi Kaneda, Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Osaka, Japan
  • Yoshiki Sawa, Department of Cardiovascular Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan
  • Ken Suzuki, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
  • Masanori Aikawa, Brigham and Women’s Hospital, Harvard Medical School, 3 Blackfan Street, 17th Floor, Boston, MA, USA
  • Koji Nishida, Department of Ophthalmology, Graduate School of Medicine, Osaka University, Osaka, Japan